Emerging Medical Therapies in Inflammatory Bowel Disease
|
|
- Oscar Welch
- 6 years ago
- Views:
Transcription
1 Emerging Medical Therapies in Inflammatory Bowel Disease Nir Modiano, MD, PhD Assistant Professor of Medicine Division of Gastroenterology & Hepatology Director, Inflammatory Bowel Disease Program
2 Disclosures I have been a Consultant for: Takeda 23andme
3 Learning Objectives We will review: New & emerging medication options in Crohn s disease and Ulcerative Colitis Mechanisms under investigation Status of clinical trials
4 Treatment of IBD: A Rapid Evolution Vedolizumab Ustekinumab Sulfasalazine, Steroids Antibiotics, Mercaptopurine Budesonide 5-ASA Methotrexate (Mesalamine) Infliximab Secondgeneration TNF biologics ?? After Rutgeerts, Rev Gastroenterol Disord 2004; 4 (Suppl 3): S3 S9
5 New & Emerging Medical Therapies Recently FDA Approved 2 new classes: Ustekinumab (anti-il12/23) Crohn s Vedolizumab (anti-α 4 β 7 ) Crohn s and UC Advanced Pipeline Trials Include: Mongersen (SMAD7) Ozanimod (S1P1-R) Tofacitinib (JAK1+3 antagonist) Etrolizumab (Interleukin blocker)
6 Emerging Therapies in IBD: *** *** From: Mehmet Coskun, Severine Vermeire, and Ole Haagen Nielsen, Trends in Pharma Sciences 2017.
7 Emerging Therapies in IBD: Biologics vs. Small Molecules Two Major Types of New Drugs: Small Molecules - Made using organic chemistry, often cheaper - Usually oral, daily meds - Can be made generic Biologics - Made in Cell Culture Line, a bioreactor (expensive) - Typically are antibodies that bind to a protein in the body - Must be given IV or as a shot - Long half life means weeks between doses - Cannot make generic but can make biosimilar
8 Clinical Trial Phases Preclinical Trials Phase I Phase II Phase III FDA Approval? Phase IV Lab and Animal Studies Small study In healthy Human Volunteers Initial Safety Assessment Medium Size Study In Patients Is it Effective? Large Study In Patients Is it truly Effective and Reasonably Safe? Large Studies Of Real Patients
9 * CD trial at OHSU * UC trial at OHSU From: Mehmet Coskun, Severine Vermeire, and Ole Haagen Nielsen, Trends in Pharma Sciences 2017.
10 Outline 1. IL12/23 Pathway Biologics 2. Jak Pathway Small Molecules 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
11 Outline 1. IL12/23 Pathway Biologics. 2. Jak Pathway Small Molecules 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
12 Ustekinumab Biologic agent (Fully humanized mab) Now approved for Plaque Psoriasis, Psoriatic arthritis, Crohn s Targets IL12b (p40) subunit of IL12/IL23 This cytokine pathway affects T-Cell differentiation GWAS (genetic studies) implicate IL12/IL23 with Crohn s IL12/23 implicated in colitis animal model
13 Ustekinumab and CD4 T-Cell Differentiation P40 =IL12B Th1 Response INF-γ Th17 response IL-17,21,22,26 From Benson et al; Nature Biotech 29(7), 2011
14 IL-12/23 as Therapeutic Targets in IBD: Ustekinumab From Benson et al; Nature Biotech 29(7), 2011
15 Ustekinumab Crohn s Phase III Data From Feagan et al., NEJM parallel Phase III trials -UNITI-1 had patients with more severe Crohn s who had already tried TNF biologics, -UNITI-2 had milder Crohn s and fewer patients had Already tried TNF biologics.
16 IL23 Therapies In Phase III data for Crohn s, and in 5 year data in Psoriasis patients, there was no signal for increased serious adverse events vs. placebo though it does modulate the immune system IL-23 is now thought to be the major driver of Ustekinumab efficacy Multiple biologics are in Phase II development targeting the p19 subunit specific to IL-23 Ustekinumab is currently in Phase III trials for UC
17 Outline 1. IL12/23 Pathway Biologics 2. Jak Pathway Small Molecules. 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
18 Emerging Therapies in IBD: JAK Pathway From Choi et al., Clinic Rev Allerg Immunol 2015 IL-12, IL-23, and other interleukins bind to a cell surface receptor and mediate their intracellular effects in part through Janus Kinase (JAK) molecules. Could we develop a small molecule that can enter cells and block JAK function?
19 Emerging Therapies in IBD: Tofacitinib Phase II study in UC met endpoints for clinical response and remission JAK Inhibitor modulates multiple cytokines involved in lymphocyte activation, function, and proliferation Approved for RA. Adverse: Infections, neutropenia, lymphoma, skin cancer (NMSC), increase in cholesterol Similar molecule, Filgotinib, also in Phase III for UC and CD Completed Phase III promising data emerging will be filing for FDA review! Sandborn et al.; NEJM 2012
20 Outline 1. IL12/23 Pathway Biologics 2. Jak Pathway Small Molecules 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
21 Emerging Therapies in IBD: Promoting TGF-β1 TGF-β1activates a receptor on the cell surface that promotes anti-inflammatory properties x If we could block SMAD7, Then TGF-β1 s anti- Inflammatory actions can kick in SMAD7 Blocks TGF-β1signaling Through SMAD2 activation! If we can inhibit the inhibitor of an inhibitor of inflammation The net result would be less inflammation! SMAD7 is very active in IBD
22 Antisense DNA Therapy? - Mongersen A radically new concept in IBD treatment developed by an Italian company, and now sold to Celgene Mongersen is an oral Smad7 antisense oligonucleotide * How does Antisense DNA Work? * DNA is transcribed to mrna from which a protein is made (mrna is a copy to the original blueprint for making a specific protein) Antisense DNA is designed to match and bind to the mrna, preventing translation into the protein, and targeting the mrna for degradation.
23 Antisense DNA Therapy? Mongersen is an oral Smad7 antisense oligonucleotide. Locally active in gut with negligible systemic absorption. Phase II trial in active Crohn s disease (by CDAI) suggests it may work! AE s similar to placebo Now in Phase III for Crohn s Met primary endpoint of clinical remission at day 15 (based on CDAI) Monteleone G. et al., NEJM 2015
24 Antisense DNA Therapy? Mongersen trial surprises: 1. Very quick dramatic effect 2. Response maintained at 12 weeks but treatment was only first 2 weeks! -May promote immune tolerance? 3. Clinical remission did not depend on baseline CRP, nor did treatment lower CRP. This is puzzling. - Medications effective in IBD usually work better for symptoms when CRP is higher, indicating true inflammation. Monteleone G. et al., NEJM 2015 Monteleone G. et al. [Italy] #826 DDW 2015
25 Outline 1. IL12/23 Pathway Biologics 2. Jak Pathway Small Molecules 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
26 Intergrin / Anti-Adhesion Mechanisms 1. These are biologics that block the handshake when a white blood cell traveling through the bloodstream reaches the gut. 2. First was Natalizumab Effective in Crohn s, but also blocked the white cells from entering the brain. This meant that it worked for Multiple Sclerosis too BUT is associated with a serious brain infection called PML (progressive multifocal leukoencephalopathy) 3. Vedolizumab was designed to be specific for the gut NO PML. - Blocks α 4 β 7 located on circulating B and T lymphocytes which interacts specifically with MAdCAM-1 on intestinal vascular endothelium 4. Vedolizumab now approved for Crohn s and UC. - Advantages: Favorable risk profile, no systemic immunosuppression - Disadvantages: Takes 3-4 months to work, when it works. 5. Other gut-specific treatments are in development: - Etrolizumab and Anti-MAdCAM-1
27 Anti-MadCAM Study in UC Figure from Lobaton T. et al, AP&T 2014 Phase II trial of a novel biologic in Moderate-Severe UC Target is MadCAM-1 on high endothelial venules, which bind to α4β7 integrin on subsets of WBC s. Similar mechanism to Vedolizumab Does not affect brain immunity. Reinisch W. et al., #901a DDW 2015
28 Anti-MadCAM Turandot Study in UC Met primary and secondary endpoints; noted dose response peaks in bell shape Calprotectin drop with drug but not placebo Safety profile appears similar to placebo Proceeding to Phase III with 22.5 mg dose (28% mucosal healing seen with this dose) Reinisch W. et al., #901a DDW 2015
29 Outline 1. IL12/23 Pathway Biologics 2. Jak Pathway Small Molecules 3. SMAD7 Antisense Oligonucleotide (Mongersen) 4. Integrin Blockers block white cells from reaching gut 5. S1P1 Receptor Blockers block white cells from exiting lymph nodes
30 Ozanimod/Receptos (S1P1R Modulator) TOUCHSTONE Study Phase II Randomized DB PC trial of oral S1P1 Receptor Modulator in moderate-severe UC Ozanimod induces S1P1R internalization subset of autoreactive lymphocytes are retained in lymph nodes (note drop in lymphocyte count) Sandborn WJ, et. al. NEJM 2016 and Sandborn WJ, et. al. #445 DDW 2015
31 Ozanimod/Receptos (S1P1R Modulator) Phase II Study 197 patients, divided 1:1:1 Met efficacy endpoints at week 8 with dose response seen. No notable cardiac, ophthlamologic, or infectious AE s; did note drop in lymphocyte counts Sandborn WJ, et. al. NEJM 2016 Sandborn WJ, et. al. #445 DDW 2015
32 Sandborn WJ, et. al. NEJM 2016 Ozanimod/Receptos (S1P1R Modulator) Touchstone Study Maintenance Possible bradycardia and liver test changes NOTE: Fingolimod works by same mechanism (approved for MS) - Has had some side effects including slow heart rate, macular edema, and uncommon serious infections.
33 Emerging Therapies in IBD: Conclusions Therapeutic options have been rapidly growing in IBD Many new therapies, including oral therapies, are advancing in clinical trials Mechanisms generally involve blocking pro-inflammation pathways OR blocking white blood cells from getting out of the lymph nodes and into the gut. Future studies needed to: Compare efficacy of treatments (in a class and between classes) Identify ahead of time who will respond to what class of treatment!
34 Emerging Therapies in IBD: Clinical Trials at OHSU We are currently enrolling for two investigational new drug studies in IBD: 1. Ozanimod (S1P1R blocker, oral small molecule) for Moderate to Severe Ulcerative Colitis. 2. Mongersen (SMAD7 Antisense Therapy) for Crohn s Disease.
35 OHSU IBD Program Judy Collins, MD Kian Keyashian, MD Nir Modiano, MD, PhD Rebecca Matro, MD OHSU Colorectal Surgeons: Dan Herzig, MD Liana Tsikitis, MD Kim Lu, MD Stephanie Hill, RN Jullane Hohnstein, MA
Future Directions in IBD: Treatments & Approaches
Future Directions in IBD: Treatments & Approaches JASON HARPER, MD CROHN S & COLITIS FOUNDATION PATIENT EDUCATION SEMINAR MARCH 26, 2017 Outline Introduction Clinical trials: Logistics & Expectations Novel
More informationNEW THERAPEUTIC OPTIONS FOR THE MANAGEMENT OF IBD
NEW THERAPEUTIC OPTIONS FOR THE MANAGEMENT OF IBD ATILLA ERTAN, MD, FACP, MACG, AGAF Professor & Interim Division Chief Division of GI, Hepatology and Nutrition UT Health McGovern Medical School Director,
More informationBiologics in IBD: Optimizing Therapies and Emerging Agents
Optimizing Therapies and Emerging Agents Peter Mannon, MD Professor of Medicine and Microbiology UAB AGS Annual Conference July 1, 2017 Hilton Sandestin Optimizing Therapies and Emerging Agents Optimizing
More informationBIOLOGIC AND BIOSIMILAR MEDICATIONS
BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC AND BIOSIMILAR MEDICATIONS IN THE TREATMENT OF IBD Crohn s disease and ulcerative colitis are the two main forms
More informationRedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL)
RedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL) MAP US Phase III Positive Top-Line Results RHB-104 for Crohn s Disease July 30, 2018 Disclaimer and Forward Looking Statements No representation or warranty
More informationDiverse Threads in IBD Clinical Development: Will a more durable treatment approach emerge?
Diverse Threads in IBD Clinical Development: Will a more durable treatment approach emerge? 2 / September 2016 Informa UK Ltd 2016 (Unauthorized photocopying prohibited.) Laura Runkel, PhD Associate Director,
More informationThis presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America
This presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America The development of this presentation was supported in 2016 by a sponsorship
More informationBIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD. crohnsandcolitis.ca
BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD crohnsandcolitis.ca BIOLOGIC MEDICATIONS IN THE TREATMENT OF IBD INFLAMMATION AND IMMUNITY IN CROHN S AND COLITIS Inflammation is the body s normal and natural
More informationWhy even have this talk? Disclosures. What will biosimilars mean for us? Annual Revenue Due to Adalimumab. Biosimilars 2017: What We Need to Know
Biosimilars 2017: What We Need to Know Why even have this talk? Miguel Regueiro, M.D. Professor of Medicine IBD Clinical Medical Director Senior Medical Lead, Specialty Medical Homes University of Pittsburgh
More informationOptimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances
Optimizing the Development of Biosimilars Using PK/PD: Recent Scientific and Regulatory Advances Jian Wang, MD, PhD Chief, Clinical Evaluation Division Biologics and Genetic Therapies Directorate Health
More informationDrug Development in Inflammatory Bowel Disease: The FDA Perspective
Drug Development in Inflammatory Bowel Disease: The FDA Perspective Kerry Jo Lee, M.D. Division of Gastroenterology and Inborn Errors Products U.S. Food and Drug Administration 1 Disclosure Kerry Jo Lee,
More informationTreatment: Nutrition and Medication
INFLAMMATORY BOWEL DISEASE (IBD): CROHN S DISEASE Treatment: Nutrition and Medication While there is no cure for Crohn s disease, there are a number of options to help treat it. The goals of treatment
More informationREFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST Executive Summary Sales for Ulcerative Colitis in Canada In 2012, GlobalData estimated that Canada Ulcerative
More informationCompanion Diagnostics in Autoimmune Disorders: Improving Outcomes Through Personalized Medicine
Companion Diagnostics in Autoimmune Disorders: Improving Outcomes Through Personalized Medicine Carrie Brodmerkel, PhD Immunology Biomarkers Janssen R&D 1 Immune-Mediated Diseases Rheumatoid Arthritis
More informationREFERENCE CODE GDHC342DFR PUBLICAT ION DATE FEBRUARY 2014 ENTYVIO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC342DFR PUBLICAT ION DATE FEBRUARY 2014 ENTYVIO (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Entyvio in the 8MM Ulcerative Colitis (UC)
More informationREFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary Sales for Ulcerative Colitis in the United States In 2012,
More informationDrug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research
Drug Development: Why Does it Cost so Much? Lewis J. Smith, MD Professor of Medicine Director, Center for Clinical Research Associate VP for Research Drug Development Process by which new chemical entities
More informationResults from the open-label extension of NOR-SWITCH, a randomized switching trial in Norway
Results from the open-label extension of NOR-SWITCH, a randomized switching trial in Norway LIS-møte, Trondheim 21 mars 2018 Guro Løvik Goll MD PhD Kristin Kaasen Jørgensen MD PhD On behalf of the NOR-SWITCH
More informationBackground on JAKs. Goldman Sachs
Background on JAKs What is the science behind the JAK? Inflammatory cytokines specifically bind to Type I and II receptors and rely upon the JAK-STAT pathway to transmit their signal from the cell surface
More information90% 80% 70% 60% 50% 40% 30% 20% 10% 0%
Exhibit 19: Key Psoriasis Clinical Trials (Phase 3) Data compiled not from head-to-head studies Exhibit 20: Long-Term Response PASI-90 and PASI-100 (Phase 3) Data compiled not from head-to-head studies.
More informationDeveloping Novel Treatments for Autoimmune Diseases
ACCELERATED PATH TO CURES Developing Novel Treatments for Autoimmune Diseases WWW.LANDOSBIOPHARMA.COM Landos Strengths Scientific, Clinical and Business Leadership 2 Expandable Oral Therapeutic Pipeline
More informationRedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL)
RedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL) Analyst and Investor Webcast on RHB-104 for Crohn s Disease Tuesday, May 15, 2018 Disclaimer and Forward Looking Statements This presentation does not constitute
More informationClinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259
Clinical Policy: (Tysabri) Reference Number: CP.PHAR.259 Effective Date: 07/16 Last Review Date: 07/17 Coding Implications Revision Log See Important Reminder at the end of this policy for important regulatory
More informationAnti-TNF s: Still the Best First Line Therapy for IBD Treatment?
Anti-TNF s: Still the Best First Line Therapy for IBD Treatment? Pfizer Symposium - Reaching New Horizons with Biosimilars in IBD Karen I. Kroeker May 26, 2017 Disclosure of Commercial Support This program
More informationACG Public Forum. Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD. Monday, 12:45 pm 2:15 pm
ACG Public Forum Join ACG, the FDA, and EMA for a discussion on biosimilars and IBD Monday, 12:45 pm 2:15 pm Biosimilars for IBD: What the Gastroenterologist Needs to Know Tara Altepeter, MD Clinical Team
More informationEngage with us on Twitter: #Molecule2Miracle
Engage with us on Twitter: #Molecule2Miracle Kassy Perry President & CEO Perry Communications Group PhRMA Alliance Development Consultant.@kassyperry Emily Burke, Ph.D. Director of Curriculum BioTech
More informationEmerging biologics in inflammatory bowel disease
J Gastroenterol (2017) 52:141 150 DOI 10.1007/s00535-016-1283-0 REVIEW Emerging biologics in inflammatory bowel disease Heyson Chi-hey Chan 1 Siew Chien Ng 1 Received: 17 October 2016 / Accepted: 27 October
More informationThe Future Role of Biosimilars: An Unknown Frontier in IBD Treatment
The Future Role of Biosimilars: An Unknown Frontier in IBD Treatment Miguel Regueiro, MD, FACG Professor of Medicine Medical Director, IBD Center Senior Medical Lead, Specialty Homes University of Pittsburgh
More informationCADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION
CADTH CANADIAN DRUG EXPERT COMMITTEE FINAL RECOMMENDATION INFLIXIMAB (Inflectra Hospira Healthcare Corporation) Indications: Crohn Disease and Ulcerative Colitis Please refer to the CADTH Canadian Drug
More informationPublished on The YODA Project (
Principal Investigator First Name: Mirjana Last Name: Stanic Benic Degree: MD Primary Affiliation: UHC Rijeka E-mail: mirji.stanic@gmail.com Phone number: 00385992367664 Address: Kresimirova 42e Kresimirova
More informationNSE Grantees Meeting December 2015
NSE Grantees Meeting December 2015 The Spherical Nucleic Acid (SNA) Nanoparticle Changes the Paradigm for Oligo Therapeutics Linear DNA SNA Each company limited by chemistry, modality, and tissue of interest
More informationImmunity for Life TM. Sven Rohmann VP Business Development
Immunity for Life TM Sven Rohmann VP Business Development Disclaimer This Presentation includes and is based, inter alia, on forward-looking information and statements that are subject to risks and uncertainties
More informationJP Morgan Healthcare Conference January 9, 2012
JP Morgan Healthcare Conference January 9, 2012 SAFE HARBOR Certain statements in this presentation concerning our future growth prospects are forward-looking statements, which are subject to a number
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: (Tysabri) Reference Number: CP.CPA.206 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Coding Implications Revision Log See Important Reminder at the end
More informationBL-7040: Oligonucleotide for Inflammatory Bowel Disease
BL-7040: Oligonucleotide for Inflammatory Bowel Disease December 2012 Forward Looking Statements This presentation contains "forward-looking statements." These statements include words like "may," "expects,"
More informationPromise and Pitfalls of MicrobiomeModulating Methods for Inflammatory
Promise and Pitfalls of MicrobiomeModulating Methods for Inflammatory and Autoimmune Diseases Arpita Maiti, PhD Senior Director, External Science & Innovation Pfizer Inc. June 29, 2017 Boston Forward-looking
More informationREFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1106CFR PUBLICATION DATE M AY 2013 PSORIASIS - Psoriasis - US Drug Forecast and Market Analysis to Executive Summary Sales for Psoriasis in the US 2012 We estimate the 2012 PsO drug
More informationNovel targets, better molecules
Novel targets, better molecules Investor Presentation November 2014 Copyright 2014 Galapagos NV Disclaimer This presentation has been prepared by Galapagos and is furnished to you by Galapagos solely for
More informationREFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Apriso in the 10MM Ulcerative Colitis (UC)
More informationREFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022 Executive Summary The below mentioned table presents the key metrics for Crohn s
More informationBiosimilar Monoclonal- a reality
Biosimilar Monoclonal- a reality 2 nd MENA Regulatory Conference on Bioequivalence, Biowaivers, BIOANALYSIS, DISSOLUTION AND BIOSIMILARS Jordan DATE September 15-17, 2015 PRESENTED BY Rodeina Challand
More informationCelgene Announces Acquisition of Receptos. July 14, 2015
Celgene Announces Acquisition of Receptos July 14, 2015 Agenda Bob Hugin, Celgene Chairman & Chief Executive Officer Strategic Overview Scott Smith, Celgene President of Global Inflammation and Immunology
More informationClosed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD
Draft guideline on biosimilar monoclonal antibodies Closed Workshop on biosimilar monoclonal antibodies and immunogenicity of monoclonal antibodies October 2011 Dr Christian K Schneider, MD CHMP Biosimilar
More informationDeborah Dunsire, M.D. President and CEO. Annual Meeting of Shareholders Cambridge, MA May 4, 2006
Deborah Dunsire, M.D. President and CEO Annual Meeting of Shareholders Cambridge, MA May 4, 2006 2006 Millennium 2006 Pharmaceuticals Millennium Inc. Pharmaceuticals, Inc. Agenda 2005 Key Accomplishments
More informationMatthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International
Challenges in translating a candidate antibody to clinical development Matthias Grossmann, MD PhD Principal Consultant Early Phase 2013 PAREXEL International Agenda Early clinical development of therapeutic
More informationIntroducing MN-166 Multiple Sclerosis. July 9, 2008
Introducing MN-166 A New Treatment Paradigm for Multiple Sclerosis July 9, 2008 MediciNova, Inc. 2008 Forward-Looking Statements Statements in this presentation that are not historical in nature constitute
More informationREFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Uceris in the 10MM Ulcerative Colitis (UC)
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Department of Origin: Pharmacy Department(s) Affected: Integrated Healthcare Services and Pharmacy 09/13/18 Pharmacy Criteria Document: Biologics for Psoriatic Arthritis: infliximab, Orencia, and Simponi
More informationIntegrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016
Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016 Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d
More informationNanotechnology: A Brief History and Its Convergence with Medicine. Weston Daniel, PhD Director of Program Management
Nanotechnology: A Brief History and Its Convergence with Medicine Weston Daniel, PhD Director of Program Management Outline Introduction The Nanoscale Applications Realization of a Vision There s Plenty
More informationA Physician s consideration towards Biosimilars. João Eurico Fonseca
A Physician s consideration towards Biosimilars João Eurico Fonseca Disclosure I received unrestricted research grants or acted as a speaker for Abbvie, Amgen, BMS, Celtrion, Celgene, Janssen, MSD, Novartis,
More informationThe evidence for switching stable patients to Inflectra
The evidence for switching stable patients to Inflectra Professor Silvio Danese Symposium co-chair Date of preparation: March 2017 PP-IFA-GLB-0551 Disclosures Silvio Danese has served as speaker, consultant
More informationPipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016
For more information contact us Pipeline Drug Evidence Review: Ocrevus (ocrelizumab) vs. Tysabri, Lemtrada, Rebif and Tecfidera June 8, 2016 Copyright. 2016 Advera Health Analytics, Inc. All rights reserved.
More informationTrubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007
Trubion Investor Presentation BioCentury NewsMakers in the Biotech Industry Conference September 6, 2007 Peter Thompson, M.D., FACP President, CEO and Chairman Trubion Pharmaceuticals, Inc. Safe Harbor
More informationGenentech Contacts: Media: Tara Cooper (650) Investor: Kathee Littrell (650)
NEWS RELEASE Genentech Contacts: Media: Tara Cooper (650) 225-5505 Investor: Kathee Littrell (650) 225-1034 XOMA Media/Investor Contacts: Laura Zobkiw (510) 204-7273 Peter Davis (510) 204-7231 FDA APPROVES
More informationProfessor Tore Kristian Kvien, MD, PhD, Norway
GaBI Scientific Meetings 10 October 2018, Le Meridien Dubai, United Arab Emirates 2nd MENA Stakeholder Meeting on Regulatory Approval, Clinical Settings, Interchangeability and Pharmacovigilance of Biosimilars
More informationTOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017
TOP PAPERS FROM 2016: IBD & BIOSIMILARS CYNTHIA SEOW MBBS(HONS), MSC, FRACP UNIVERSITY OF CALGARY CDDW, BANFF, AB MARCH 5, 2017 FINANCIAL INTEREST DISCLOSURE (OVER THE PAST 24 MONTHS) Speaker: Janssen,
More informationREFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013
REFERENCE CODE GDHC1113CFR PUBLICATION DATE M AY 2013 PSORIASIS - Executive Summary Sales for Psoriasis in China 2012 2022 We estimate the 2012 PsO drug sales to be $392.2m in China. By forecast end in
More informationRE: Considerations in Demonstrating Interchangeability With a Reference Product; Draft Guidance for Industry; Availability (FDA 2017 D )
May 19, 2017 Scott Gottlieb, MD Commissioner U.S. Food and Drug Administration 10903 New Hampshire Avenue Silver Spring, MD 20993 RE: Considerations in Demonstrating Interchangeability With a Reference
More informationCustomized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases. Europe Microbiome Congress London, 14 Nov., 2018
Customized Phage Therapies To Eradicate Harmful Bacteria In Chronic Diseases Europe Microbiome Congress London, 14 Nov., 2018 Biomx At A Glance We are a microbiome drug discovery company developing customized
More informationleading the way in research & development
leading the way in research & development people. passion. possibilities. ABBVIE 2 immunology AbbVie Immunology has a demonstrated record of success in identifying and developing both small molecule and
More informationAndrew Nesbitt, PhD. Disclaimer 10/10/2014. Determining the Immunogenicity of Biologics: a Tricky Problem. Employee of UCB ן
Determining the Immunogenicity of Biologics: a Tricky Problem Andrew Nesbitt, PhD UCB Director Cimzia PST Disclaimer 2 Employee of UCB The theories expressed in this presentation are the views of the speaker
More informationTARGETING THE IMMUNE SYSTEM TO ELIMINATE INFLAMMATORY AND VIRAL DISEASE. Reprioritizing towards InflammatoryDiseases February 2019
TARGETING THE IMMUNE SYSTEM TO ELIMINATE INFLAMMATORY AND VIRAL DISEASE Reprioritizing towards InflammatoryDiseases February 2019 Forward looking statements This presentation contains information pertaining
More informationREFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022
REFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - Executive Summary Table below provides a summary of the key metrics for Simponi in the 10MM Ulcerative Colitis (UC)
More informationProtalix BioTherapeutics Corporate Update. June 2016
Protalix BioTherapeutics Corporate Update June 2016 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationAuto-Immune Diseases: Mechanisms of Immune Dysregulation. Hervé Sroussi DMD, PhD
Auto-Immune Diseases: Mechanisms of Immune Dysregulation Hervé Sroussi DMD, PhD Describe fundamental concepts in the development and maturation of immune cells. Explain basic mechanisms of central and
More informationBiogen Idec Neurology Pipeline. Alfred Sandrock, MD, PhD SVP, Neurology Research & Development
Biogen Idec Neurology Pipeline Alfred Sandrock, MD, PhD SVP, Neurology Research & Development March 25, 2009 Robust Neurology Pipeline Neurology Multiple Sclerosis Discovery Pre-Clinical Phase 1 Phase
More informationUpdate on New MS Therapeutics
Update on New MS Therapeutics William Meador, MD Assistant Professor AAN August 2017 Meeting Disclosures Clinical Trial Involvement: SPRINT-MS Trial MediciNova, ibudilast LemCog Sanofi/Genzyme, alemtuzumab
More informationMedication Prior Authorization Form
(Orelizumab) Policy Number: 1073 Policy History Approve Date: 05/19/2017 Effective Date: 05/19/2017 Preauthorization All Plans Benefit plans vary in coverage and some plans may not provide coverage for
More informationAbivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients
Press Release Abivax reports impressive results in clinical phase 2a trial of ABX464 as an oral treatment for ulcerative colitis patients Randomized, double-blind, placebo-controlled clinical trial shows
More informationApproval of a drug under this criteria document does not ensure full coverage of the drug.
Criteria Document: Reference #: PC/B006 Page 1 of 5 and Therapeutics Quality PRODUCT APPLICATION: PreferredOne Administrative Services, Inc. (PAS) ERISA PreferredOne Administrative Services, Inc. (PAS)
More informationFREQUENTLY ASKED QUESTIONS
CLINICAL TRIALS FREQUENTLY ASKED QUESTIONS PARTICIPATING IN A CLINICAL TRIAL What is a clinical trial? Clinical trials are research studies that involve people. Through clinical trials, researchers find
More informationCourse Agenda. Day One
Course Agenda BioImmersion: Biotech for the Non-Scientist A three-day, in-depth course that provides the background required for understanding today s fast-paced biotech marketplace. Beginning with an
More informationNational MS Society Information Sourcebook
National MS Society Information Sourcebook www.nationalmssociety.org/sourcebook Interferons The interferons are a group of natural proteins that are produced by human cells in response to viral infection
More informationCOMPANY OVERVIEW. Dinesh V. Patel, PhD President & CEO
COMPANY OVERVIEW Dinesh V. Patel, PhD President & CEO September 2017 Forward Looking Statements This presentation contains forward-looking statements of Protagonist Therapeutics, Inc. All statements other
More informationStrategies for Assessment of Immunotoxicology in Preclinical Drug Development
Strategies for Assessment of Immunotoxicology in Preclinical Drug Development Rebecca Brunette, PhD Scientist, Analytical Biology SNBL USA Preclinical Immunotoxicology The study of evaluating adverse effects
More informationUstekinumab Induction and Maintenance Therapy in Refractory Crohn s Disease
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article Ustekinumab Induction and Maintenance Therapy in Refractory Crohn s Disease William J. Sandborn, M.D., Christopher Gasink, M.D., Long-Long
More informationThe Latest Therapies for MS: Weighing Respective Benefits and Risks
Transcript Details This is a transcript of an educational program accessible on the ReachMD network. Details about the program and additional media formats for the program are accessible by visiting: https://reachmd.com/programs/frontlines-multiple-sclerosis/the-latest-therapies-for-ms-weighingrespective-benefits-and-risks/9639/
More information7th Annual Shanghai Symposium on Clinical and Pharmaceutical Solutions through Analysis
Mechanistic Physiological PhysioPD Models in Drug Development: A Proven Quantitative Systems Pharmacology (QSP) approach Sharan A Pagano SVP, Scientific Alliances at Rosa & Co. LLC 7th Annual Shanghai
More informationLicense Agreement of Tildrakizumab for Psoriasis in Europe
License Agreement of Tildrakizumab for Psoriasis in Europe July 28 th 2016 Disclaimer This document has been prepared by Almirall, S.A. (the Company ) exclusively for use during the presentation. This
More informationBiosimilar mabs Clinical issues Regulatory perspective
Biosimilar mabs Clinical issues Regulatory perspective EMEA Workshop on Biosimilar Monoclonal Antibodies, MD BMWP Chairman European Medicines Agency (EMEA), UK Paul-Ehrlich-Institut, Germany Mechanisms
More informationNonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies. Whitney S. Helms, PhD IOM, February 29,2016
Nonclinical Data to Support FIH Clinical Trials for Cancer Immunotherapies Whitney S. Helms, PhD IOM, February 29,2016 Disclaimer The views disseminated in this talk are my own and do not necessarily represent
More informationProtalix BioTherapeutics Corporate Update. September 2018
Protalix BioTherapeutics Corporate Update September 2018 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities
More informationProtalix BioTherapeutics Corporate Update. June 2017
Protalix BioTherapeutics Corporate Update June 2017 Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act
More informationThe Gut Microbiome: Where to look for Biomarkers
The Gut Microbiome: Where to look for Biomarkers Microscopic Image showing Skin cells at 20x magnification Carrie Brodmerkel, PhD Head, Immunology Biomarkers June 25, 2018 Agenda Where you can measure
More informationNatalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update
Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin Complementarity-Determining Regions (CDRs) Multiple Sclerosis Treatment Update CDR grafted from murine Ab Human IgG 4 framework
More informationRedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL) RHB-104 Phase III Crohn s Disease Program Update October 2, 2017
RedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL) RHB-104 Phase III Crohn s Disease Program Update October 2, 2017 Disclaimer and Forward Looking Statements 2 This presentation does not constitute an offer or
More informationImmunogenicity of Therapeutic Proteins. Steven J Swanson, Ph.D. Executive Director, Clinical Immunology
Immunogenicity of Therapeutic Proteins Steven J Swanson, Ph.D. Executive Director, Clinical Immunology swanson@amgen.com Causes of Immunogenicity Sequence differences between therapeutic protein and endogenous
More informationDeciphering the Genes for Resilience
Deciphering the Genes for Resilience Jeffrey Bland, PhD Chairman Emeritus The Institute for Functional Medicine Founder & President The Personalized Lifestyle Medicine Institute Understanding of the biochemical
More informationTechnology appraisal guidance Published: 28 September 2016 nice.org.uk/guidance/ta407
Secukinumab for active ankylosing spondylitis after treatment with non- steroidal anti-inflammatory drugs or TNF-alpha inhibitors Technology appraisal guidance Published: 28 September 16 nice.org.uk/guidance/ta407
More informationInnovations in Early Clinical Trial Designs: Application to New Drug Development in Pharma
Innovations in Early Clinical Trial Designs: Application to New Drug Development in Pharma Robert Schmouder, MD, MPH Translational Medicine Head Novartis Institutes for BioMedical Research (NIBR) Cambridge,
More informationBiological and Functional Analysis of
Biological and Functional Analysis of Biosimilar TNFαDrugs Daniel N Galbraith Chief Scientific Officer, BioOutsource Ltd. Reliable quality, on time, every time Drug Characterisation Activities Functional
More informationThe rescue therapy company. July Patrick McLean Chief Executive Officer. Company Background
The rescue therapy company July 2007 Patrick McLean Chief Executive Officer Company Background Formed in 2004 to develop and commercialise the Borody / Centre for Digestive Diseases patents Listed in September
More informationSpecialty medicine: Pearls from the PBMI conference, Scottsdale, Arizona Dr. Elsa Badenhorst
Specialty medicine: Pearls from the PBMI conference, Scottsdale, Arizona 2012 Dr. Elsa Badenhorst The Magic Bullet Paul Ehrlich (1854-1915) if a compound could be made that selectively targeted a diseasecausing
More informationPress Release. RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn s Disease
Press Release RedHill Biopharma Announces Positive Top-Line Results from Phase III Study of RHB-104 in Crohn s Disease Primary endpoint successfully achieved - superior remission rate at week 26 in patients
More informationLeading the world in novel adult stem cell therapies Half-Year Financial Results
Leading the world in novel adult stem cell therapies 2013 Half-Year Financial Results CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS This presentation, including any comments made during or following
More informationSynactPharma AB. A new medicine to treat inflammatory diseases. Sedermera Dagen Copenhagen, March 13, 2018
SynactPharma AB A new medicine to treat inflammatory diseases Jeppe Øvlesen, MBA CEO Thomas Jonassen, MD CSO Sedermera Dagen Copenhagen, March 13, 2018 SYNACT PHARMA OVERVIEW Synact Pharma AB listed at
More informationA blood sample will be collected annually for up to 2 years for JCV antibody testing.
Mellen Center Currently Enrolling Non-Treatment Trials STRATIFY-2 JCV Antibody Program in Patients with Relapsing Multiple Sclerosis Receiving or Considering Treatment with Tysabri Primary Investigator:
More informationBiosimilars Scientific and Regulatory Considerations
Biosimilars Scientific and Regulatory Considerations Gustavo Grampp Regulatory Policy Director, Amgen Presented at Maryland Pharmacists Association meeting January 31, 2016 Program objectives 1. Review
More informationStructure of IgG and IgM
Structure of IgG and IgM Fig. 5-1 A,B Crystal Structure of Secreted IgG Fig. 5-1 C Structure of an Ig Domain Fig. 5-2 Proteolytic Fragments of IgG (1) Fig. 5-3A Proteolytic Fragments of IgG (2) Fig. 5-3B
More information